Tạp chí Tim mạch học Việt Nam

Article detail

Article detail description

Home
CA LÂM SÀNG Issue: Số 118

Genetic testing and counseling in pulmonary arterial hypertension

Dao Thi Trang: Hanoi Medical University;
Published: November 28, 2025
Views: 62

Abstract

Pulmonary arterial hypertension (PAH) is an uncommon autosomal dominant condition that may result from germline pathogenic variants. Currently, 10 genes have been definitively associated with hereditary PAH (HPAH), and several other genes have been identified through advancements in genome sequencing technology. Genetic testing and counseling are recommended for individuals with idiopathic (primary) pulmonary arterial hypertension (PAH), PAH linked to anorexigens, or those with a familial history. We present a case of PAH that received molecular diagnosis and genetic counseling for the ACVRL1 gene. Identifying pathogenic variants associated with PAH is crucial for screening asymptomatic carriers among family members, determining which individuals require regular assessment, and prenatal genetic counseling.

References

1.
Morrell NW, Aldred MA, Chung WK, et al. Genetics and genomics of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801899. doi:10.1183/13993003.01899-2018
2.
Austin ED, Loyd JE. The Genetics of Pulmonary Arterial Hypertension. Circ Res. 2014;115(1):189-202. doi:10.1161/CIRCRESAHA.115.303404
3.
Zhang X, Zhang C, Li Q, Piao C, Zhang H, Gu H. Clinical characteristics and prognosis analysis of idiopathic and hereditary pulmonary hypertension patients with ACVRL1 gene mutations. Pulm Circ. 2021;11(4):1-8. doi:10.1177/20458940211044577
4.
Li L, Jick S, Breitenstein S, Hernandez G, Michel A, Vizcaya D. Pulmonary arterial hypertension in the USA: an epidemiological study in a large insured pediatric population. Pulm Circ. 2017;7(1):126-136. doi:10.1086/690007
5.
Evans JDW, Girerd B, Montani D, et al. BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis. Lancet Respir Med. 2016;4(2):129-137. doi:10.1016/S2213-2600(15)00544-5
6.
Souza R, Humbert M, Sztrymf B, et al. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J. 2008;31(2):343-348. doi:10.1183/09031936.00104807
7.
Welch CL, Chung WK. Genetics and Genomics of Pediatric Pulmonary Arterial Hypertension. Genes. 2020;11(10):1213. doi:10.3390/genes11101213
8.
Chida A, Shintani M, Yagi H, et al. Outcomes of childhood pulmonary arterial hypertension in BMPR2 and ALK1 mutation carriers. Am J Cardiol. 2012;110(4):586-593. doi:10.1016/j.amjcard.2012.04.035
9.
Girerd B, Montani D, Coulet F, et al. Clinical outcomes of pulmonary arterial hypertension in patients carrying an ACVRL1 (ALK1) mutation. Am J Respir Crit Care Med. 2010;181(8):851-861. doi:10.1164/rccm.200908-1284OC
10.
Waite KA, Eng C. From developmental disorder to heritable cancer: it’s all in the BMP/TGF-beta family. Nat Rev Genet. 2003;4(10):763-773. doi:10.1038/nrg1178

Files

Article Views62
Document Views4
Downloads0
Section CA LÂM SÀNG
Issue Số 118
Pages 165-171